Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04050462 · ClinicalTrials.gov registry record · Phase 2
Nivolumab Combined With BMS-986253 in HCC Patients
A Phase 2 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT04050462 is a Phase 2 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 13 participants.
The verdict
NCT04050462, a Phase 2 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
A phase II clinical trial is utilized to examine whether BMS-986253 (25 subjects) or Cabiralizumab (25 subjects) when combined with Nivolumab offers improved radiographic objective response rates (ORR) over Nivolumab monotherapy (25 subjects) in advanced HCC patients.
Interventions
- DRUG Nivolumab 240 mg IV every 2 weeks + Cabiralizumab 4 mg/kg IV every 2 weeks
- DRUG Nivolumab 240 mg IV every 2 weeks + BMS-986253 1200 mg IV every 2 weeks
- DRUG Nivolumab 240 mg IV every 2 weeks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-09-12 |
| Est. Completion | 2025-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04050462
The ClinicalTrials.gov registry entry for NCT04050462 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nivolumab 240 mg IV every 2 weeks + Cabiralizumab 4 mg/kg IV every 2 weeks is the first listed.
NCT04050462 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04050462 about?
NCT04050462 is a clinical study titled "Nivolumab Combined With BMS-986253 in HCC Patients". A phase II clinical trial is utilized to examine whether BMS-986253 (25 subjects) or Cabiralizumab (25 subjects) when combined with Nivolumab offers improved radiographic objective response rates (ORR) over Nivolumab monotherapy (25 subjects) in advanced HCC patients.
What is the current status of trial NCT04050462?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2019-09-12. Estimated completion is 2025-01-31.
What interventions are being tested in trial NCT04050462?
The interventions under investigation include: Nivolumab 240 mg IV every 2 weeks + Cabiralizumab 4 mg/kg IV every 2 weeks (DRUG), Nivolumab 240 mg IV every 2 weeks + BMS-986253 1200 mg IV every 2 weeks (DRUG), Nivolumab 240 mg IV every 2 weeks (DRUG).
Who is sponsoring clinical trial NCT04050462?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.